ClearPoint Neuro (NASDAQ:CLPT) Price Target Raised to $25.00

ClearPoint Neuro (NASDAQ:CLPT) had its price objective raised by analysts at Stifel Nicolaus from $19.00 to $25.00 in a research report issued on Tuesday,Benzinga reports. The firm currently has a “buy” rating on the stock. Stifel Nicolaus’ price objective would suggest a potential upside of 110.26% from the company’s current price.

Several other analysts have also issued reports on CLPT. Lake Street Capital boosted their price objective on shares of ClearPoint Neuro from $17.00 to $30.00 and gave the company a “buy” rating in a report on Tuesday, January 21st. B. Riley boosted their target price on ClearPoint Neuro from $15.00 to $20.00 and gave the stock a “buy” rating in a research note on Tuesday, January 28th.

ClearPoint Neuro Trading Down 0.7 %

CLPT opened at $11.89 on Tuesday. The firm has a market capitalization of $328.54 million, a PE ratio of -17.23 and a beta of 1.06. ClearPoint Neuro has a twelve month low of $5.11 and a twelve month high of $19.22. The firm’s 50-day moving average price is $15.67 and its 200 day moving average price is $14.04.

ClearPoint Neuro (NASDAQ:CLPT) last posted its quarterly earnings results on Wednesday, February 26th. The company reported ($0.20) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.15) by ($0.05). ClearPoint Neuro had a negative net margin of 59.64% and a negative return on equity of 62.10%. The company had revenue of $7.77 million during the quarter, compared to analysts’ expectations of $8.23 million. As a group, analysts predict that ClearPoint Neuro will post -0.66 earnings per share for the current fiscal year.

Institutional Investors Weigh In On ClearPoint Neuro

A number of large investors have recently modified their holdings of CLPT. Conway Capital Management Inc. purchased a new stake in ClearPoint Neuro during the third quarter worth approximately $1,586,000. JPMorgan Chase & Co. increased its position in ClearPoint Neuro by 58.7% in the 3rd quarter. JPMorgan Chase & Co. now owns 9,770 shares of the company’s stock valued at $110,000 after acquiring an additional 3,612 shares during the period. Barclays PLC raised its stake in ClearPoint Neuro by 24.3% during the 3rd quarter. Barclays PLC now owns 5,674 shares of the company’s stock valued at $64,000 after acquiring an additional 1,109 shares during the last quarter. Geode Capital Management LLC lifted its position in ClearPoint Neuro by 1.5% during the 3rd quarter. Geode Capital Management LLC now owns 287,294 shares of the company’s stock worth $3,222,000 after acquiring an additional 4,170 shares during the period. Finally, Bradley Foster & Sargent Inc. CT purchased a new position in shares of ClearPoint Neuro in the 4th quarter valued at approximately $871,000. 30.08% of the stock is owned by hedge funds and other institutional investors.

About ClearPoint Neuro

ClearPoint Neuro, Inc operates as a medical device company primarily in the United States. It develops and commercializes platforms for performing minimally invasive surgical procedures in the brain under magnetic resonance imaging guided interventions. The company offers ClearPoint system, an integrated system for the insertion of deep brain stimulation electrodes, biopsy needles, and laser catheters, as well as the infusion of pharmaceuticals into the brain.